Asset Details
Do you wish to reserve the book?
Road to clinical efficacy: challenges and novel strategies for antimicrobial peptide development
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Road to clinical efficacy: challenges and novel strategies for antimicrobial peptide development
Do you wish to request the book?
Road to clinical efficacy: challenges and novel strategies for antimicrobial peptide development
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Road to clinical efficacy: challenges and novel strategies for antimicrobial peptide development
2011
Overview
Since the discovery of magainins, cecropins and defensins 30 years ago, antimicrobial peptides (AMPs) have been hailed as a potential solution to the dearth of novel antibiotic development. AMPs have shown robust activity against a wide variety of pathogens, including drug-resistant bacteria. Unlike small-molecule antibiotics, however, AMPs have failed to translate this success to the clinic. Only the polymyxins, gramicidins, nisin and daptomycin are currently approved for medical use; the latter is the only example to have been developed in the last several decades. Nonetheless, researchers continue to isolate, modify and develop novel AMPs for therapeutic applications. Efforts have focused on increasing stability, reducing cytotoxicity, improving antimicrobial activity and incorporating AMPs in novel formulations, including nanoscale particles. As peptide synthesis and recombinant production methodologies improve, and more relevant bioassays become available, it becomes increasingly likely that AMPs will break the regulatory barrier and enter the marketplace as valuable antimicrobial weapons in the next 10 years.
Publisher
Future Medicine Ltd
Subject
/ Antimicrobial Cationic Peptides - adverse effects
/ Antimicrobial Cationic Peptides - chemistry
/ Antimicrobial Cationic Peptides - pharmacokinetics
/ Antimicrobial Cationic Peptides - pharmacology
/ Bacteria
/ Communicable Diseases - drug therapy
/ Drug Evaluation, Preclinical - methods
/ Humans
/ Lipids
/ Peptides
/ Proteins
/ specifically targeted antimicrobial peptide
/ Studies
/ toxicity
